The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo induction followed by GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple sclerosis (RMS) and (2) to explore the changes in lymphocyte populations in the CNS as a consequence of treatment with rituximab followed by chronic GA therapy.